Searchable abstracts of presentations at key conferences in endocrinology

ea0032p993 | Thyroid (non-cancer) | ECE2013

Levothyroxine requirements in thyroidectomized diabetic patients receiving metformin

Zafon Carles , Casteras Anna , Obiols Gabriel , Mesa Jordi

Background: Recent studies suggest that metformin (MF) may reduce TSH concentration. This fact could imply a dosage reduction of levothyroxine among those hypothyroid patients taking metformin.Aim: To determine, in a retrospective analysis, the impact of metformin in thyroidectomized patients (a condition not influenced by endogenous thyroid hormone production) on levothyroxine replacement.Patients and methods: One hundred ninety t...

ea0022p798 | Thyroid | ECE2010

Usefulness of sorafenib in the management of advanced thyroid carcinoma

Obiols Gabriel , Capdevila Jaume , Zafon Carles , Mesa Jordi

One of the most important activating genetic aberrations in differentiated thyroid cancer (DTC) development pathways involves the RET/PTC–RAS–RAF–MAPK axis. Mutations in the RET gene are essential in medullary thyroid carcinoma (MTC). Sorafenib is the first compound to reach clinical practice that is capable of inhibiting all the RAF kinases. Moreover, it targets a panel of tyrosine kinase receptors, such as VEGF receptors which gives to sorafenib not only proap...

ea0037ep872 | Thyroid cancer | ECE2015

Role of thyroglobulin as a predictor of the evolution of disease in differentiated thyroid cancer

Biagetti Betina , Zafon Carles , Garcia-Burillo Amparo , Velasco Monica , Obiols Gabriel , Castell Joan , Mesa Jordi

Aim: Investigate, in patients with differentiated thyroid cancer (DTC) if thyroglobulin (Tg) values, immediately before and six months post radioiodine ablation are good predictors of disease progression.Materials and methods: Basal Tg values (Tg-B) and rhTSH stimulated Tg (Tg-S) before ablation (0) and 6 months later (6) from 142 DTC patients, with post-surgical ablation therapy between 2003 and 2009 with a follow up of 5 years, were analysed.<p cla...

ea0037ep905 | Thyroid cancer | ECE2015

Efficacy and safety of an outpatient low radioide dose for remnant thyroid ablation in low risk papillary thyroid carcinoma (PTC)

Obiols Gabriel , Garcia-Burillo Amparo , Zafon Carles , Castell Joan , Mesa Jordi

In PTC, radioiodine required dose for thyroid remnant ablation is uncertain. Recent works show that low doses may be sufficient for low risk patients.Aim: To evaluate the efficacy and safety of thyroid remnant ablation in patients with low-risk PTC by using 1100 MBq (30 mCi) outpatient doses.Materials and methods: Twenty-five patients (24 women, 55 years-old mean age, range 34–77) referred for ablation of postsurgical thyroid ...

ea0022p778 | Thyroid | ECE2010

Clinical and histological different features in the form of presentation between papillary microcarcinomas and papillary carcinomas of larger size

Zafon Carles , Fort Jose Manuel , Baena Juan Antonio , Castellvi Josep , Obiols Gabriel , Monroy Gabriela , Mesa Jordi

Background and aim: Papillary thyroid carcinomas (PTCs) with a diameter <1 cm are referred to as papillary microcarcinomas (PTMCs). They are being diagnosed with increasing frequency. Within this type of tumour some clinical and histological characteristics with prognostic and therapeutic impact have been proposed. In the present study we describe the clinical and pathological presentation of PTMCs and compare them with papillary thyroid carcinomas of larger size.<p cl...

ea0073pep5.7 | Presented ePosters 5: Thyroid | ECE2021

Multifocality in papillary thyroid carcinoma. Is it always the same tumor?

Efrain Cordero-Vazquez. , Iglesias Carmela , Sesé Marta , Somoza Rosa , Javier Hernandez-Losa , Zafon Carles

IntroductionMultifocality is a common finding in papillary thyroid carcinoma (PTC), but its biological significance is not well established. In some cases not all foci present the same histological pattern.ObjectiveTo study the different histological patterns and molecular profiles of multifocal PTC (mPTC).Material and methodsAll patients with a confirmed diagnosi...

ea0041gp223 | Thyroid Cancer | ECE2016

Macro, but not micrometastases, detected by OSNA technique are related with more aggressive papillary thyroid cancer features

Zafon Carles , Iglesias Carmela , Gonzalez Oscar , Temprana Jordi , Caubet Enric , Garcia-Burillo Amparo , Obiols Gabriel , Serres Xavier , Mesa Jordi

Introduction: Classically, risk stratification in papillary thyroid carcinoma (PTC) assigned the same magnitude of risk to all patients with regional lymph node involvement (N1 disease). However, specific lymph node characteristics (such as size, number, extension, etc.) will allow individualizing treatment and follow-up. One-Step Nucleic Acid Amplification (OSNA) measures the number of copies of mRNA of cytokeratin 19 (CK19) as a marker of lymph node metastasis. Thus, copy nu...

ea0056p34 | Adrenal cortex (to include Cushing's) | ECE2018

Value of 131I-Norcholesterol scintigraphy in the evaluation of primary hyperaldosteronism

Casteras Anna , Villasboas-Rosciolesi Diego , Garcia-Burillo Amparo , Espinel Eugenia , Zafon Carles , Mesa Jordi , Castell-Conesa Joan

Background: 131I-norcholesterol scintigraphy (INCS) is currently not considered a main confirmatory and localizing study in primary aldosteronism (PA), however few recent data is available. On the other hand, adrenal venous sampling (AVS) is technically difficult, and may also lead to erroneuos diagnosis.Aim: To describe the performance of INCS, done under dexamethasone (DXM) supression, in daily practice.Patients and methods: Retr...

ea0049gp235 | Thyroid Cancer | ECE2017

Clinical Utility of response to therapy in combination with BRAF in risk assessment of thyroid cancer

Fernandez Laura Perez , De la Vieja Escolar Antonio , Zafon Carles , Galofre Juan Carlos , Riesco-Eizaguirre Garcilaso , Spanish Task Force for the study of BRAF SEEN Garcilaso

Response to therapy re-stratification approach has been recently included in the 2015 ATA guidelines as a risk-adapted approach to management of thyroid cancer. Our aim was to investigate the clinical utility of response to therapy variables obtained during early follow-up in combination with BRAF, a prominent oncogene in thyroid cancer with prognostic value. This was a retrospective multicenter study of 871 patients at 11 centers in Spain with papillary thyroid cancer followe...

ea0041ep1102 | Thyroid cancer | ECE2016

Management and transcendence of incidental thyroid 18FDG-PET focal uptake (PEToma)

Roman Anna Casteras , Liopis Carles Zafon , Burillo Amparo Garcia , Rosciolesi Diego Villasboas , Pujanell Maite Salcedo , Duran Jaime Monturiol , Conesa Joan Castell , Manteca Jordi Mesa

Introduction: Incidental focal uptake in the thyroid gland is detected in 1%–2% of 18FDG-PET examinations. FNA is recommended due to an increased risk of malignancy (25–50%), but these figures are extracted from the studied cases (about a half). Moreover there is controversy about the maximum standardized uptake value (Suvmax) ability to discriminate between benign or malignant nodules.Methods: We retrospectively reviewed 4207 FDG-PE...